Y253H mutation appearing in a μ-BCR-ABL (e19a2) CML

Leukemia Research

Volumn 32, Issue 2, 2008, Pages 361-362

  Popovici, Cornel ^a   Charbonnier, Aude ^a   Gisserot, Olivier ^b   Aguilon, Philippe ^b   Rémy, Virginie ^a   Olschwang, Sylviane ^a   Mozziconacci, Marie Joëlle ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b Military Teaching Hospital Sainte Anne   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB;

AGED; ANAMNESIS; ANASARCA; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG BINDING; DYSPNEA; FEMALE; GENE; GENE LOCATION; GENE MUTATION; GENETIC TRANSCRIPTION; HEART FAILURE; HUMAN; LOW DRUG DOSE; MULTIPLEX POLYMERASE CHAIN REACTION; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; Y253H GENE;

AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PIPERAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLES;

EID: 38949205900     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.03.001     Document Type: Article

References (5)

1. Pane F., Intrieri M., Quintarelli C., Izzo B., Casadei Muccioli G., and Salvatore F. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene 21 (2002) 8652-8667
2. Lee J.J., Kim H.J., Kim Y.J., Lee S., Hwang J.Y., Kim Y.L., et al. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts. Leukemia 18 (2004) 1539-1540
3. Van Dongen J.J., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., Saglio G., et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukaemia for detection of minimal residual disease. Report of the BIOMOED-1 Concerted Action: investigation of minimal residual disease in acute leukaemia. Leukemia 13 (1999) 1901-1928
4. Nicolini F.E., Corm S., Lê Q.H., Sorel N., Hayette S., Bories D., et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospectve analysis from the French intergroup of CML (Fi(p)-LMC GROUP). Leukemia 20 (2006) 1061-1066
5. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 (2006) 2531-2541